“The findings from the DOLCE study build on the robust body of evidence supporting its use in treatment-naive adults living ...

The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.

Gilead is committed to designing trials to help understand how HIV treatment and prevention impact populations that have been ...

head of the HIV Prevention Trials Network says there are four areas of research which are being investigated in HIV; ...

Immuno Cure’s ICVAX aims to induce broadly reactive polyfunctional viral-specific T cells to achieve sustained HIV-1 ...

Researchers remain hopeful that they're heading in the right direction to finding a cure for HIV, the virus that causes AIDS. Right now, it’s still out of reach. But the unusual cases of four ...

A new study from Tulane University finds that historical race-based lending practices are still impacting health today, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment ...

Due to positive results, the trial will conclude earlier than expected, reducing the number of recruitments. “These findings ...

A study of nearly 1,000 gay male couples in The Lancet found no cases of HIV transmission over eight years. This was due to treatment reducing the virus to very low levels in the body.

Dr Philip Arandjelovic, co-author in the study, said the discovery is an exciting step towards developing treatment options for the tens of millions of people currently living with HIV globally.

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...